Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout
Authors:
- 5 August 2011
- journal article
- case report
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 14 (3) , e33-e37
Abstract
Since the discovery of the inflammasome, interleukin 1 production has been found to be integral in the pathophysiology of gout. Interleukin 1 inhibition by Anakinra has been shown to effective for the treatment of gout. We report three cases of resistant chronic tophaceous gout who responded to anakinra subcutaneous injections on an intermittent basis.Keywords
This publication has 12 references indexed in Scilit:
- The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnnals of the Rheumatic Diseases, 2009
- Case of anakinra as a steroid‐sparing agent for gout inflammationArthritis Care & Research, 2009
- Efficacy and safety of rilonacept (interleukin‐1 trap) in patients with cryopyrin‐associated periodic syndromes: Results from two sequential placebo‐controlled studiesArthritis & Rheumatism, 2008
- Developments in the scientific and clinical understanding of goutArthritis Research & Therapy, 2008
- Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinraAnnals of the Rheumatic Diseases, 2007
- The changing epidemiology of goutNature Clinical Practice Rheumatology, 2007
- A pilot study of IL-1 inhibition by anakinra in acute goutArthritis Research & Therapy, 2007
- New insights into gout epidemiologyCurrent Opinion in Rheumatology, 2006
- Gout-associated uric acid crystals activate the NALP3 inflammasomeNature, 2006
- Pathogenesis of GoutAnnals of Internal Medicine, 2005